Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Rob Jones reviews: practice-affirming and -changing data in prostate cancer

Robert Jones • 18 Jan 2019
ESMO 2018
Genitourinary Cancer Prostate Cancer Abiraterone
LATITUDE STAMPEDE

From the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Robert Jones, MD, PhD, of the University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, presents and analyzes interesting results from clinical trials for prostate cancer. Prof. Jones reflects on the STAMPEDE (NCT00268476) and LATITUTDE (NCT01715285) trials, investigating the role of abiraterone in prostate cancer. He also discusses another STAMPEDE analysis, of patients with metastatic disease who are receiving ADT for the first time, investigating whether radiotherapy to the primary tumor will improve survival time.

More from Robert Jones

2:04
Areas of unmet need in metastatic urothelial carcinoma
Robert Jones • 4 Jun 2022
1:10
ASCO 2022: genitourinary cancer highlights
Robert Jones • 4 Jun 2022
0:58
Replacing the current standard of care for urothelial carcinoma
Robert Jones • 4 Jun 2022
2:19
Final results from ATLANTIS cabozantinib arm for urothelial carcinoma
Robert Jones • 4 Jun 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals